Eli Lilly and Company (NYSE:LLY) Shares Purchased by Leeward Financial Partners LLC

Leeward Financial Partners LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 51.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 6,422 shares of the company's stock after purchasing an additional 2,195 shares during the period. Eli Lilly and Company accounts for about 1.8% of Leeward Financial Partners LLC's holdings, making the stock its 17th biggest holding. Leeward Financial Partners LLC's holdings in Eli Lilly and Company were worth $4,958,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after purchasing an additional 60,306 shares in the last quarter. Polymer Capital Management HK LTD acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $443,000. Point72 Asset Management L.P. purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at $11,657,000. Petrus Trust Company LTA acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $668,000. Finally, Quantinno Capital Management LP boosted its position in Eli Lilly and Company by 27.5% during the third quarter. Quantinno Capital Management LP now owns 61,268 shares of the company's stock worth $54,280,000 after acquiring an additional 13,202 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $12.10 during trading on Tuesday, reaching $735.83. The stock had a trading volume of 1,890,804 shares, compared to its average volume of 3,657,094. The stock has a market cap of $697.69 billion, a PE ratio of 62.84, a P/E/G ratio of 1.40 and a beta of 0.51. The firm's 50 day moving average price is $846.64 and its two-hundred day moving average price is $830.05. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Remove Ads

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has initiated a share repurchase plan on Monday, December 9th that permits the company to buyback $15.00 billion in shares. This buyback authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. Wells Fargo & Company increased their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Citigroup decreased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. Truist Financial upped their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Finally, Bank of America reiterated a "buy" rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,018.89.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.